NCT06946485View on ClinicalTrials.gov

Universal Anti-CD70 CAR-T (CHT101) Cell Therapy for Relapsed Refractory Systemic Lupus Erythematosus

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

April 1, 2025

Primary Completion Date

February 28, 2026

Study Completion Date

March 31, 2027

Conditions
Systemic Lupus Erythematosus (SLE)
Interventions
BIOLOGICAL

Universal anti-CD70 CAR-T (CHT101)

Universal anti-CD70 CAR-T (CHT101) cell therpy

Trial Locations (1)

Unknown

RECRUITING

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Nanjing

All Listed Sponsors
lead

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

OTHER